The CONQUER Trial, an innovative clinical study aimed at addressing nicotine addiction using the VapeAway filter system, is now recruiting participants. Sponsored by VapeAway and listed on ClinicalTrials.gov, this trial targets individuals seeking alternatives to quit smoking. Its focus is on measuring cessation success rates and behavioral changes linked to e-cigarette reduction. Professionals in the medical device, clinical, and regulatory sectors may find this announcement noteworthy.
In this article:
- What is the CONQUER Trial?
- Who can participate?
- What is the VapeAway filter system?
- Clinical and regulatory implications
- FAQs
- Conclusion and next steps
- Disclaimer
- Full announcement information
What is the CONQUER Trial?
The CONQUER Trial stands for Cessation of Nicotine, Quitting with E-cigarette Reduction. Its primary aim is to evaluate the effectiveness of the VapeAway filter system in helping users reduce nicotine intake and eventually quit e-cigarettes. Success will be measured through behavioral and clinical outcomes.
Sponsored by VapeAway, a company known for their innovative smoking cessation devices, this clinical trial seeks to deliver measurable results that could impact current practices in the treatment of nicotine addiction. As of January 2026, recruitment has begun, offering a chance for smokers or vaping individuals to engage in structured assistance programs backed by medical device technology.
Who can participate?
Participants interested in the study must meet certain conditions, primarily revolving around nicotine addiction and the willingness to engage with the device throughout the trial period. It is open to individuals who actively use e-cigarettes and are seeking non-invasive solutions for cessation.
An advisory from VapeAway indicates that details about inclusion, exclusion, or follow-up protocols may be provided to participants during initial screening. Potential patients are encouraged to check ClinicalTrials.gov for further enrollment information.
What is the VapeAway filter system?
The VapeAway filter system is a specialized device created to assist with e-cigarette reduction. It works by modifying vaping habits gradually, providing users with a controlled and systematic method to cut down on nicotine. The device has been designed with user safety, ease of use, and regulatory compliance in mind.
No claims regarding its efficacy or clinical performance were independently verified in this announcement. This device, according to regulatory guidelines, must adhere to performance and safety evaluations while demonstrating its intended purpose throughout the clinical study.
More technical details are available via VapeAway’s official documentation and ClinicalTrials.gov, where additional transparency on device testing and trials can be accessed.
Clinical and regulatory implications
Nicotine addiction remains a global health challenge, and innovation in medical devices for cessation offers new opportunities to improve public health strategies. The CONQUER Trial represents a promising intersection of consumer-friendly devices and scientific inquiry.
Regulatory teams observing this study should note its design as aligned with ClinicalTrials.gov protocols, ensuring compliance with clinical documentation and data integrity standards. Devices such as VapeAway will likely undergo scrutiny against MDR Annex XIV principles, particularly in Europe, where evidence-backed claims remain key.
The broader implications include potential adoption of successful devices by healthcare providers, pending trial outcomes and regulatory clearances. As medical professionals and quality teams monitor developments, the trial may present advancements in usability testing and patient-centric design.
FAQs
1. What is the intended duration of the CONQUER Trial?
The stated duration is approximately one year, though final timelines depend on recruitment progress and subsequent phases.
2. Is the VapeAway filter system FDA-cleared?
At the time of this publication, no FDA clearance has been disclosed. The device will undergo rigorous safety and performance evaluations as required.
3. How can individuals sign up?
Interested participants should follow the registration process via ClinicalTrials.gov. Visit the official link to learn more.
4. What are the success indicators for this trial?
Success will be measured using cessation rates, reduction in nicotine dependence, and behavioral improvements during the study.
Conclusion and next steps
The CONQUER Trial introduces a significant opportunity for research and innovation in medical device-assisted smoking cessation. Regulatory teams, clinicians, and patients alike will watch the outcomes of this initiative closely as recruitment advances. Those working in regulatory affairs can draw inspiration from this case for future device trials.
Disclaimer
This informational post is for professionals in clinical, regulatory, and quality sectors. It is not legal advice. Readers are advised to consult with legal experts regarding compliance issues specific to nicotine dependence devices.
Full announcement information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07322432?term=medical+device